# Atezolizumab Plus Bevacizumab in First Line NSCLC Patients

> **NCT03836066** · PHASE2 · COMPLETED · sponsor: **Fundación GECP** · enrollment: 41 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Atezolizumab-Bevacizumab

## Key facts

- **NCT ID:** NCT03836066
- **Lead sponsor:** Fundación GECP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-15
- **Primary completion:** 2024-10-21
- **Final completion:** 2024-10-21
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03836066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03836066, "Atezolizumab Plus Bevacizumab in First Line NSCLC Patients". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03836066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*